Ugur Sahin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7354462/publications.pdf

Version: 2024-02-01

201 papers	42,988 citations	12330 69 h-index	2895 190 g-index
219 all docs	219 docs citations	219 times ranked	45223 citing authors

#	Article	IF	Citations
1	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine, 2020, 383, 2603-2615.	27.0	11,472
2	Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New England Journal of Medicine, 2020, 383, 2439-2450.	27.0	2,107
3	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature, 2017, 547, 222-226.	27.8	1,806
4	COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature, 2020, 586, 594-599.	27.8	1,520
5	mRNA-based therapeutics â€" developing a new class of drugs. Nature Reviews Drug Discovery, 2014, 13, 759-780.	46.4	1,501
6	Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature, 2016, 534, 396-401.	27.8	1,243
7	PhaseÂI/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature, 2020, 586, 589-593.	27.8	1,197
8	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. New England Journal of Medicine, 2021, 385, 1761-1773.	27.0	1,090
9	Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature, 2015, 520, 692-696.	27.8	1,030
10	Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. New England Journal of Medicine, 2021, 385, 239-250.	27.0	709
11	Exploiting the Mutanome for Tumor Vaccination. Cancer Research, 2012, 72, 1081-1091.	0.9	706
12	Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nature Biotechnology, 1999, 17, 555-561.	17.5	703
13	Personalized vaccines for cancer immunotherapy. Science, 2018, 359, 1355-1360.	12.6	697
14	Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature, 2019, 565, 240-245.	27.8	637
15	A vaccine targeting mutant IDH1 induces antitumour immunity. Nature, 2014, 512, 324-327.	27.8	613
16	BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature, 2021, 595, 572-577.	27.8	583
17	Neutralizing Activity of BNT162b2-Elicited Serum. New England Journal of Medicine, 2021, 384, 1466-1468.	27.0	528
18	An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature, 2020, 585, 107-112.	27.8	526

#	Article	IF	Citations
19	BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature, 2021, 592, 283-289.	27.8	494
20	Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccineâ€“elicited human sera. Science, 2021, 371, 1152-1153.	12.6	485
21	Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood, 2006, 108, 4009-4017.	1.4	457
22	Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. New England Journal of Medicine, 2022, 386, 35-46.	27.0	431
23	SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. New England Journal of Medicine, 2021, 385, 1627-1629.	27.0	346
24	Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics, 2014, 15, 190.	2.8	334
25	BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature, 2021, 596, 273-275.	27.8	318
26	Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses. Molecular Therapy, 2018, 26, 446-455.	8.2	315
27	Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccineâ€“elicited human sera. Science, 2022, 375, 678-680.	12.6	303
28	Serological identification of human tumor antigens. Current Opinion in Immunology, 1997, 9, 709-716.	5.5	292
29	An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science, 2020, 367, 446-453.	12.6	286
30	A Facile Method for the Removal of dsRNA Contaminant from InÂVitro-Transcribed mRNA. Molecular Therapy - Nucleic Acids, 2019, 15, 26-35.	5.1	271
31	Intranodal Vaccination with Naked Antigen-Encoding RNA Elicits Potent Prophylactic and Therapeutic Antitumoral Immunity. Cancer Research, 2010, 70, 9031-9040.	0.9	253
32	A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science, 2021, 371, 145-153.	12.6	253
33	Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development. Clinical Cancer Research, 2008, 14, 7624-7634.	7.0	247
34	A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin Î¹ C as a Compatible Prognostic Marker in Human Solid Tumors. Clinical Cancer Research, 2012, 18, 2695-2703.	7.0	237
35	Molecular Definition of a Novel Human Galectin Which Is Immunogenic in Patients with Hodgkin's Disease. Journal of Biological Chemistry, 1997, 272, 6416-6422.	3.4	223
36	Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. New England Journal of Medicine, 2022, 386, 1910-1921.	27.0	215

#	Article	IF	Citations
37	HLA typing from RNA-Seq sequence reads. Genome Medicine, 2012, 4, 102.	8.2	204
38	Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3â€² UTRs Identified by Cellular Library Screening. Molecular Therapy, 2019, 27, 824-836.	8.2	191
39	SSX: A multigene family with several members transcribed in normal testis and human cancer. International Journal of Cancer, 1997, 72, 965-971.	5.1	190
40	Serological analysis of human tumor antigens: molecular definition and implications. Trends in Molecular Medicine, 1997, 3, 342-349.	2.6	185
41	Elimination of large tumors in mice by mRNA-encoded bispecific antibodies. Nature Medicine, 2017, 23, 815-817.	30.7	182
42	IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nature Immunology, 2022, 23, 532-542.	14.5	178
43	Identification of neoantigens for individualized therapeutic cancer vaccines. Nature Reviews Drug Discovery, 2022, 21, 261-282.	46.4	173
44	An RNA toolbox for cancer immunotherapy. Nature Reviews Drug Discovery, 2018, 17, 751-767.	46.4	171
45	mRNA therapeutics in cancer immunotherapy. Molecular Cancer, 2021, 20, 69.	19.2	168
46	Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes. Science Immunology, 2022, 7, .	11.9	144
47	Expression ofSSX genes in human tumors. , 1998, 77, 19-23.		143
48	Increased Antigen Presentation Efficiency by Coupling Antigens to MHC Class I Trafficking Signals. Journal of Immunology, 2008, 180, 309-318.	0.8	141
49	Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines. Clinical Cancer Research, 2016, 22, 1885-1896.	7.0	128
50	The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. MBio, 2022, 13, e0297921.	4.1	117
51	Tumor vaccination using messenger RNA: prospects of a future therapy. Current Opinion in Immunology, 2011, 23, 399-406.	5.5	114
52	Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nature Medicine, 2021, 27, 1062-1070.	30.7	114
53	A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform. Journal of Virology, 2015, 89, 11654-11667.	3.4	108
54	Polysarcosine-Functionalized Lipid Nanoparticles for Therapeutic mRNA Delivery. ACS Applied Nano Materials, 2020, 3, 10634-10645.	5.0	108

#	Article	IF	Citations
55	Proteasome-Assisted Identification of a SSX-2-Derived Epitope Recognized by Tumor-Reactive CTL Infiltrating Metastatic Melanoma. Journal of Immunology, 2002, 168, 1717-1722.	0.8	106
56	Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: Basis for polyvalent CT vaccine strategies. , 1998, 78, 387-389.		99
57	A Trans-amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity. Molecular Therapy, 2020, 28, 119-128.	8.2	99
58	HLA and proteasome expression body map. BMC Medical Genomics, 2018, 11, 36.	1.5	95
59	Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model. Frontiers in Oncology, 2020, 10, 1195.	2.8	94
60	BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. New England Journal of Medicine, 2021, 385, 472-474.	27.0	93
61	A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines. OncoImmunology, 2014, 3, e954893.	4.6	92
62	A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer. European Journal of Cancer, 2018, 100, 17-26.	2.8	85
63	Multiple splice variants of lactate dehydrogenase C selectively expressed in human cancer. Cancer Research, 2002, 62, 6750-5.	0.9	84
64	A Placenta-Specific Gene Ectopically Activated in Many Human Cancers Is Essentially Involved in Malignant Cell Processes. Cancer Research, 2007, 67, 9528-9534.	0.9	82
65	Aberrantly activated claudin 6 and 18.2 as potential therapy targets in nonâ€smallâ€cell lung cancer. International Journal of Cancer, 2014, 135, 2206-2214.	5.1	82
66	Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma. Nanomedicine, 2016, 11, 2723-2734.	3.3	82
67	Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma. Cancer Discovery, 2018, 8, 1366-1375.	9.4	80
68	Cascades of transcriptional induction during dendritic cell maturation revealed by genomeâ€wide expression analysis. FASEB Journal, 2003, 17, 836-847.	0.5	79
69	Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. Science Translational Medicine, 2021, 13, eabc7804.	12.4	79
70	TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression. Genome Medicine, 2015, 7, 118.	8.2	78
71	Identification of a tumor-reactive T-cell repertoire in the immune infiltrate of patients with resectable pancreatic ductal adenocarcinoma. OncoImmunology, 2016, 5, e1240859.	4.6	75
72	Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA. Molecular Therapy - Methods and Clinical Development, 2019, 12, 32-46.	4.1	74

#	Article	IF	Citations
73	Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Letters, 2006, 236, 64-71.	7.2	71
74	Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population. Breast Cancer Research, 2018, 20, 15.	5.0	71
75	FLT3 Ligand Enhances the Cancer Therapeutic Potency of Naked RNA Vaccines. Cancer Research, 2011, 71, 6132-6142.	0.9	70
76	Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms. International Journal of Cancer, 2014, 134, 731-739.	5.1	67
77	Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond. Wiley Interdisciplinary Reviews RNA, 2015, 6, 471-499.	6.4	65
78	Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma. Japanese Journal of Clinical Oncology, 2019, 49, 870-876.	1.3	64
79	Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene, 2011, 481, 83-92.	2.2	63
80	The regulatory landscape for actively personalized cancer immunotherapies. Nature Biotechnology, 2013, 31, 880-882.	17.5	62
81	Efficient Reprogramming of Human Fibroblasts and Blood-Derived Endothelial Progenitor Cells Using Nonmodified RNA for Reprogramming and Immune Evasion. Human Gene Therapy, 2015, 26, 751-766.	2.7	61
82	Uptake of synthetic naked RNA by skin-resident dendritic cells via macropinocytosis allows antigen expression and induction of T-cell responses in mice. Cancer Immunology, Immunotherapy, 2016, 65, 1075-1083.	4.2	59
83	MS4A12 Is a Colon-Selective Store-Operated Calcium Channel Promoting Malignant Cell Processes. Cancer Research, 2008, 68, 3458-3466.	0.9	58
84	HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory. OncoImmunology, 2019, 8, e1629259.	4.6	58
85	mRNA as a Versatile Tool for Exogenous Protein Expression. Current Gene Therapy, 2012, 12, 347-361.	2.0	57
86	Hybrid Biopolymer and Lipid Nanoparticles with Improved Transfection Efficacy for mRNA. Cells, 2020, 9, 2034.	4.1	57
87	Targeting the tumor mutanome for personalized vaccination therapy. OncoImmunology, 2012, 1, 768-769.	4.6	55
88	Mutanome directed cancer immunotherapy. Current Opinion in Immunology, 2016, 39, 14-22.	5.5	55
89	Harnessing Tumor Mutations for Truly Individualized Cancer Vaccines. Annual Review of Medicine, 2019, 70, 395-407.	12.2	54
90	Tailoring the stealth properties of biocompatible polysaccharide nanocontainers. Biomaterials, 2015, 49, 125-134.	11.4	53

#	Article	IF	Citations
91	Cap analogs modified with 1,2-dithiodiphosphate moiety protect mRNA from decapping and enhance its translational potential. Nucleic Acids Research, 2016, 44, gkw896.	14.5	52
92	Characterization of zolbetuximab in pancreatic cancer models. OncoImmunology, 2019, 8, e1523096.	4.6	52
93	Synthesis, properties, and biological activity of boranophosphate analogs of the mRNA cap: versatile tools for manipulation of therapeutically relevant cap-dependent processes. Nucleic Acids Research, 2014, 42, 10245-10264.	14.5	49
94	Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer. International Journal of Cancer, 2006, 118, 2522-2528.	5.1	47
95	The Wnt/Î²-Catenin Pathway Attenuates Experimental Allergic Airway Disease. Journal of Immunology, 2014, 193, 485-495.	0.8	47
96	Simultaneous ex vivo quantification of antigen-specific CD4+ and CD8+ T cell responses using in vitro transcribed RNA. Cancer Immunology, Immunotherapy, 2007, 56, 1577-1587.	4.2	46
97	NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells. Nature Communications, 2016, 7, 11724.	12.8	46
98	Steatohepatitis Impairs T-cellâ€“Directed Immunotherapies Against Liver Tumors in Mice. Gastroenterology, 2021, 160, 331-345.e6.	1.3	46
99	Frequent Nonrandom Activation of Germ-Line Genes in Human Cancer. Cancer Research, 2004, 64, 5988-5993.	0.9	45
100	Highly Specific Auto-Antibodies against Claudin-18 Isoform 2 Induced by a Chimeric HBcAg Virus-Like Particle Vaccine Kill Tumor Cells and Inhibit the Growth of Lung Metastases. Cancer Research, 2011, 71, 516-527.	0.9	45
101	Induction of immunosuppressive functions and NF-ÎºB by FLIP in monocytes. Nature Communications, 2018, 9, 5193.	12.8	45
102	Synthetic mRNAs with Superior Translation and Stability Properties. Methods in Molecular Biology, 2013, 969, 55-72.	0.9	44
103	Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer, 2016, 16, 398.	2.6	44
104	A novel tumour associated leucine zipper protein targeting to sites of gene transcription and splicing. Oncogene, 2002, 21, 3879-3888.	5.9	43
105	Improvement ofIn VivoExpression of Genes Delivered by Self-Amplifying RNA Using Vaccinia Virus Immune Evasion Proteins. Human Gene Therapy, 2017, 28, 1138-1146.	2.7	43
106	The role of lymphocyte subsets and adhesion molecules in T cell-dependent cytotoxicity mediated by CD3 and CD28 bispecific monoclonal antibodies. European Journal of Immunology, 1995, 25, 2027-2033.	2.9	40
107	Computational dissection of tissue contamination for identification of colon cancerâ€specific expression profiles. FASEB Journal, 2003, 17, 376-385.	0.5	40
108	Molecular Characterization of Virus-induced Autoantibody Responses. Journal of Experimental Medicine, 2004, 200, 637-646.	8.5	40

#	Article	IF	Citations
109	Mutated tumor alleles are expressed according to their DNA frequency. Scientific Reports, 2014, 4, 4743.	3.3	40
110	CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer. Oncotarget, 2015, 6, 25356-25367.	1.8	40
111	Challenges towards the realization of individualized cancer vaccines. Nature Biomedical Engineering, 2018, 2, 566-569.	22.5	40
112	Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6. OncoImmunology, 2016, 5, e1091555.	4.6	39
113	Expression of serologically identified tumor antigens in acute leukemias. Leukemia Research, 2003, 27, 655-660.	0.8	37
114	mTOR Inhibition Improves Antitumor Effects of Vaccination with Antigen-Encoding RNA. Cancer Immunology Research, 2013, 1, 386-392.	3.4	37
115	Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. Cancer Discovery, 2022, 12, 1248-1265.	9.4	36
116	Functional TCR Retrieval from Single Antigen-Specific Human T Cells Reveals Multiple Novel Epitopes. Cancer Immunology Research, 2014, 2, 1230-1244.	3.4	35
117	Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry. Breast Cancer Research and Treatment, 2016, 157, 437-446.	2.5	33
118	CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: Potential use for the treatment of hodgkin's lymphoma. International Journal of Cancer, 1993, 54, 820-827.	5.1	32
119	Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics. RNA Biology, 2011, 8, 35-43.	3.1	32
120	A liposomal RNA vaccine inducing neoantigen-specific CD4 ⁺ T cells augments the antitumor activity of local radiotherapy in mice. OncoImmunology, 2020, 9, 1771925.	4.6	32
121	An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells. Oncotarget, 2016, 7, 21199-21221.	1.8	32
122	Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial. Vaccine, 2022, 40, 1483-1492.	3.8	32
123	Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection. Emerging Microbes and Infections, 2022, 11, 1828-1832.	6.5	32
124	Expression profiling of autoimmune regulator AIRE mRNA in a comprehensive set of human normal and neoplastic tissues. Immunology Letters, 2006, 106, 172-179.	2.5	31
125	Large-scale analysis of SARS-CoV-2 spike-glycoprotein mutants demonstrates the need for continuous screening of virus isolates. PLoS ONE, 2021, 16, e0249254.	2.5	31
126	Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. Cancer Research, 2020, 80, CT301-CT301.	0.9	31

#	Article	IF	Citations
127	Selective Activation of Trophoblast-specific PLAC1 in Breast Cancer by CCAAT/Enhancer-binding Protein Î² (C/EBPÎ²) Isoform 2. Journal of Biological Chemistry, 2009, 284, 28607-28615.	3.4	30
128	Confidence-based Somatic Mutation Evaluation and Prioritization. PLoS Computational Biology, 2012, 8, e1002714.	3.2	30
129	An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyperÂ®. Breast Cancer Research, 2017, 19, 55.	5.0	29
130	In vivo imaging of the immune response upon systemic RNA cancer vaccination by FDG-PET. EJNMMI Research, 2018, 8, 80.	2.5	28
131	Investigation of pH-Responsiveness inside Lipid Nanoparticles for Parenteral mRNA Application Using Small-Angle X-ray Scattering. Langmuir, 2020, 36, 13331-13341.	3.5	28
132	Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination. Journal of Immunology Research, 2015, 2015, 1-6.	2.2	27
133	Monitoring Translation Activity of mRNA-Loaded Nanoparticles in Mice. Molecular Pharmaceutics, 2018, 15, 3909-3919.	4.6	27
134	FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology, 2016, 34, LBA4001-LBA4001.	1.6	27
135	Humoral immune responses of lung cancer patients against the Transmembrane Phosphatase with TEnsin homology (TPTE). Lung Cancer, 2015, 90, 334-341.	2.0	26
136	Enhanced protection of C57 BL/6 vs Balb/c mice to melanoma liver metastasis is mediated by NK cells. OncoImmunology, 2018, 7, e1409929.	4.6	26
137	The synthesis of isopropylidene mRNA cap analogs modified with phosphorothioate moiety and their evaluation as promoters of mRNA translation. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3753-3758.	2.2	25
138	Accurate detection of tumor-specific gene fusions reveals strongly immunogenic personal neo-antigens. Nature Biotechnology, 2022, 40, 1276-1284.	17.5	25
139	Identification of Tumor-Associated Autoantigens With SEREX. , 2005, 109, 137-154.		24
140	The human X chromosome is enriched for germline genes expressed in premeiotic germ cells of both sexes. Human Molecular Genetics, 2006, 15, 2392-2399.	2.9	24
141	Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes. Clinical Cancer Research, 2016, 22, 4827-4836.	7.0	24
142	Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors. Blood Advances, 2020, 4, 5702-5715.	5.2	24
143	SeroGRID: an improved method for the rapid selection of antigens with disease related immunogenicity. Journal of Immunological Methods, 2003, 283, 261-267.	1.4	23
144	Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles. Scientific Reports, 2017, 7, 16892.	3.3	23

#	Article	IF	Citations
145	Enhanced stability of a chimeric hepatitis B core antigen virus-like-particle (HBcAg-VLP) by a C-terminal linker-hexahistidine-peptide. Journal of Nanobiotechnology, 2018, 16, 39.	9.1	23
146	Incorporation of mRNA in Lamellar Lipid Matrices for Parenteral Administration. Molecular Pharmaceutics, 2018, 15, 642-651.	4.6	23
147	Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+â€‰gastroesophageal adenocarcinoma. Gastric Cancer, 2021, 24, 721-730.	5.3	23
148	The European Regulatory Environment of RNA-Based Vaccines. Methods in Molecular Biology, 2017, 1499, 203-222.	0.9	22
149	A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults. Nature Communications, 2021, 12, 7105.	12.8	22
150	Selective activation of tumor growth-promoting Ca2+ channel MS4A12 in colon cancer by caudal type homeobox transcription factor CDX2. Molecular Cancer, 2009, 8, 77.	19.2	21
151	NCOA3 is a selective co-activator of estrogen receptor Î±-mediated transactivation of PLAC1 in MCF-7 breast cancer cells. BMC Cancer, 2013, 13, 570.	2.6	21
152	Ribozyme Assays to Quantify the Capping Efficiency of In Vitro-Transcribed mRNA. Pharmaceutics, 2022, 14, 328.	4.5	20
153	Identification of new claudin family members by a novel PSI-BLAST based approach with enhanced specificity. Proteins: Structure, Function and Bioinformatics, 2006, 65, 808-815.	2.6	19
154	Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response. OncoImmunology, 2019, 8, e1601480.	4.6	18
155	Abstract CT169: A phase Ia study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in patients with locally advanced or metastatic solid tumors. , 2020, , .		18
156	Antitumor Vaccination with Synthetic mRNA: Strategies for In Vitro and In Vivo Preclinical Studies. Methods in Molecular Biology, 2013, 969, 235-246.	0.9	17
157	Prognostic Significance of Interferon-Î³ and Its Signaling Pathway in Early Breast Cancer Depends on the Molecular Subtypes. International Journal of Molecular Sciences, 2020, 21, 7178.	4.1	17
158	Dexamethasone premedication suppresses vaccine-induced immune responses against cancer. OncoImmunology, 2020, 9, 1758004.	4.6	17
159	Autoimmunity seen through the SEREX-scope. Autoimmunity Reviews, 2003, 2, 339-345.	5.8	16
160	NFâ€ÎºB factors control the induction of NFATc1 in B lymphocytes. European Journal of Immunology, 2014, 44, 3392-3402.	2.9	16
161	A non-functional neoepitope specific CD8⁺ T-cell response induced by tumor derived antigen exposure in vivo. OncoImmunology, 2019, 8, 1553478.	4.6	16
162	CrELISA: a fast and robust enzyme-linked immunosorbent assay bypassing the need for purification of recombinant protein. Journal of Immunological Methods, 2004, 289, 191-199.	1.4	14

#	Article	IF	Citations
163	BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19. Vaccines, 2021, 9, 324.	4.4	14
164	Displaying Tetraâ€Membrane Spanning Claudins on Enveloped Virusâ€Like Particles for Cancer Immunotherapy. Biotechnology Journal, 2018, 13, e1700345.	3.5	13
165	In Silico HLA Typing Using Standard RNA-Seq Sequence Reads. Methods in Molecular Biology, 2015, 1310, 247-258.	0.9	13
166	Rapid molecular dissection of viral and bacterial immunomes. European Journal of Immunology, 2006, 36, 1049-1057.	2.9	11
167	Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy. BMC Cancer, 2019, 19, 694.	2.6	11
168	NeoFox: annotating neoantigen candidates with neoantigen features. Bioinformatics, 2021, 37, 4246-4247.	4.1	11
169	Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer. Cancer Immunology, Immunotherapy, 2022, 71, 1975-1988.	4.2	11
170	Studying Tumor-ReacTive T Cells: A Personalized Organoid Model. Cell Stem Cell, 2018, 23, 318-319.	11.1	10
171	Generation of TCR-Engineered T Cells and Their Use To Control the Performance of T Cell Assays. Journal of Immunology, 2015, 194, 6177-6189.	0.8	9
172	FLT3 Ligand as a Molecular Adjuvant for Naked RNA Vaccines. Methods in Molecular Biology, 2016, 1428, 163-175.	0.9	9
173	Discovery and Subtyping of Neo-Epitope Specific T-Cell Responses for Cancer Immunotherapy: Addressing the Mutanome. Methods in Molecular Biology, 2017, 1499, 223-236.	0.9	9
174	Personalized Neo-Epitope Vaccines for Cancer Treatment. Recent Results in Cancer Research, 2020, 214, 153-167.	1.8	9
175	Safety, tolerability, and efficacy of the first-in-class antibody IMAB362 targeting claudin 18.2 in patients with metastatic gastroesophageal adenocarcinomas.. Journal of Clinical Oncology, 2013, 31, 4080-4080.	1.6	9
176	An Fc-inert PD-L1Ã—4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation. OncoImmunology, 2022, 11, 2030135.	4.6	9
177	A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections. Molecular Therapy - Nucleic Acids, 2022, 28, 743-754.	5.1	9
178	Luciferase mRNA Transfection of Antigen Presenting Cells Permits Sensitive Nonradioactive Measurement of Cellular and Humoral Cytotoxicity. Journal of Immunology Research, 2016, 2016, 1-13.	2.2	7
179	Transferring a Quantitative Molecular Diagnostic Test to Multiple Real-Time Quantitative PCR Platforms. Journal of Molecular Diagnostics, 2018, 20, 398-414.	2.8	7
180	PLAC1 is essential for FGF7/FGFRIIIb-induced Akt-mediated cancer cell proliferation. Oncotarget, 2020, 11, 1862-1875.	1.8	7

#	Article	IF	Citations
181	Antigen Identification Using SEREX. Methods in Molecular Biology, 2013, 1061, 59-77.	0.9	6
182	Peptide microarrays enable rapid mimotope optimization for pharmacokinetic analysis of the novel therapeutic antibody IMAB362. Biotechnology Journal, 2014, 9, 545-554.	3.5	6
183	Current Developments in Actively Personalized Cancer Vaccination with a Focus on RNA as the Drug Format. Progress in Tumor Research, 2015, 42, 44-54.	0.1	6
184	In Silico Typing of Classical and Non-classical HLA Alleles from Standard RNA-Seq Reads. Methods in Molecular Biology, 2018, 1802, 177-191.	0.9	6
185	Looking for more reliable biomarkers in breast cancer: Comparison between routine methods and RT-qPCR. PLoS ONE, 2021, 16, e0255580.	2.5	6
186	Development of an RNA-based kit for easy generation of TCR-engineered lymphocytes to control T-cell assay performance. Journal of Immunological Methods, 2018, 458, 74-82.	1.4	5
187	Recognition of human tumors: SEREX expression cloning to identify tumour antigens. , 2001, , 45-57.		4
188	3D Melanoma Cocultures as Improved Models for Nanoparticle-Mediated Delivery of RNA to Tumors. Cells, 2022, 11, 1026.	4.1	4
189	BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants. Npj Vaccines, 2022, 7, 41.	6.0	4
190	ArtiFuseâ€"computational validation of fusion gene detection tools without relying on simulated reads. Bioinformatics, 2020, 36, 373-379.	4.1	3
191	Iodine-124 PET quantification of organ-specific delivery and expression of NIS-encoding RNA. EJNMMI Research, 2021, 11, 14.	2.5	3
192	Comprehensive Genomic and Transcriptomic Analysis of Three Synchronous Primary Tumours and a Recurrence from a Head and Neck Cancer Patient. International Journal of Molecular Sciences, 2021, 22, 7583.	4.1	3
193	Chromatin Immunoprecipitation Assay to Identify Genomic Binding Sites of Regulatory Factors. Methods in Molecular Biology, 2016, 1366, 53-65.	0.9	3
194	A first-in-human dose escalation and dose-finding phase I/II trial of IMAB027 in patients with recurrent advanced ovarian cancer (GM-IMAB-002-01).. Journal of Clinical Oncology, 2014, 32, TPS5623-TPS5623.	1.6	3
195	Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial. Advances in Therapy, 2022, 39, 3789-3798.	2.9	3
196	In silico strategy for detection of target candidates for antibody therapy of solid tumors. Gene, 2008, 414, 76-84.	2.2	2
197	Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies. OncoImmunology, 2015, 4, e1005523.	4.6	2
198	Robustness of biomarker determination in breast cancer by RT-qPCR: impact of tumor cell content, DCIS and non-neoplastic breast tissue. Diagnostic Pathology, 2018, 13, 83.	2.0	2

#	Article	IF	Citations
199	Identification of Human Tumor Antigens Using the B-Cell Repertoire. , 1998, , 185-198.		1
200	Abstract P5-10-13: Low influence of tumor cell content on mRNA expression levels of ESR, PGR, HER2 and KI67 when performing the MammaTyperÂ® RT-PCR kit. , 2015, , .		1
201	Past, present and future of immunology in Mainz. Cellular Immunology, 2016, 308, 1-6.	3.0	0